Latest Development in Multiple Myeloma

Imai, Yumiko

doi:10.3390/cancers12092544

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall 5 years relative survival rate was 52.2% in 2016. [3][4][5] Despite the advances of treatment, outcomes remain poor for those who are triple-class refractory (refractory to at least one class of IMiD, one class of PI and one class of anti-CD38 monoclonal Antibody) and Penta-refractory (refractory to two different IMiDs, two different PIs and one anti-CD38 monoclol antibody), with a historical median survival of 8.6 and 5.6 months, respectively, based on a large multicenter retrospective collaboration. 6 There is no consensus on the most effective treatment for tripleclass (RRMM).…”

Section: Introductionmentioning

confidence: 99%

Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)

Pennipede

Mohyuddin

Hawkins

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

Novelty StatementsWhat is the new aspect of your work? Our manuscript evaluated an alternative option for those who are heavily treated triple-class relapsed/refractory multiple myeloma using KCd. What is the central finding of your work?We notice an acceptable response rate, PFS, and OS for this group of patients. What is (or could be) the specific clinical relevance of your work?We believe that this treatment could be an additional option in this group of myeloma patients, and possible this could be considering a bridging therapy prior consideration of CAR-T cell or enrollment in a clinical trial

show abstract

Section: Introductionmentioning

confidence: 99%

Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)

Pennipede

Mohyuddin

Hawkins

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…MicroRNAs transfer between MM plasma cells and bone marrow microenvironment, enabling the development and metastasis of malignancy through messenger RNA destruction or translation inhibition ( 28 , 29 ). Circulating microRNAs have been applied in hematological diseases as diagnostic biomarkers due to their reliable stability and non-invasive properties ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematologic malignancy characterized by aberrant expansion of monoclonal plasma cells with high mortality and severe complications due to the lack of early diagnosis and timely treatment. Circulating miRNAs have shown potential in the diagnosis of MM with inconsistent results, which remains to be fully assessed. Here we updated a meta-analysis with relative studies and essays published in English before Jan 31, 2021. After steps of screening, 32 studies from 11 articles that included a total of 627 MM patients and 314 healthy controls were collected. All data were analyzed by REVMAN 5.3 and Stata MP 16, and the quality of included literatures was estimated by Diagnostic Accuracy Study 2 (QUADAS-2). The pooled area under the curve (AUC) shown in summary receiver operating characteristic (SROC) analyses of circulating miRNAs was 0.87 (95%CI, 0.81–0.89), and the sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were 0.79, 0.86, 5, 0.27, 22, respectively. Meta-regression and subgroup analysis exhibited that “miRNA cluster”, patient “detailed stage or Ig isotype” accounted for a considerable proportion of heterogeneity, revealing the importance of study design and patient inclusion in diagnostic trials; thus standardized recommendations were proposed for further studies. In addition, the performance of the circulating miRNAs included in MM prognosis and treatment response prediction was summarized, indicating that they could serve as valuable biomarkers, which would expand their clinical application greatly.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=234297, PROSPERO, identifier (CRD42021234297).

show abstract

“…MM cells express high levels of CXCR4 and the cells accurately home to the BM, where Ads are one of the most abundant cell types. The homing MM cells compete with hematopoietic cells in BM and reside there long term [13] , [14] , [15] , [16] . However, these Ads are influenced by factors in the myeloma microenvironment to become myeloma-associated Ads (MAAs) and contributed to disease progress.…”

mentioning

confidence: 99%

Bone marrow adipocytes is a new player in supporting myeloma cells proliferation and survival in myeloma microenvironment

Wei,

Zhang,

Wang

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

Latest Development in Multiple Myeloma

Abstract: Specialists in the field of multiple myeloma (MM) research have written a series of 12 articles (2 original articles, 10 reviews) in the Special Issue “Latest Development in Multiple Myeloma” [...]

Cited by 4 publications

References 15 publications

Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)

Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)

Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations

Bone marrow adipocytes is a new player in supporting myeloma cells proliferation and survival in myeloma microenvironment

Contact Info

Product

Resources

About